Massachusetts Financial Services Co. MA Acquires 15,521 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Massachusetts Financial Services Co. MA raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 406,086 shares of the company's stock after buying an additional 15,521 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.50% of IDEXX Laboratories worth $205,163,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of IDXX. American Century Companies Inc. lifted its position in IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock worth $274,179,000 after acquiring an additional 177,226 shares in the last quarter. International Assets Investment Management LLC raised its position in shares of IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock valued at $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of IDEXX Laboratories by 13.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company's stock valued at $249,855,000 after purchasing an additional 59,519 shares in the last quarter. Clearbridge Investments LLC raised its position in shares of IDEXX Laboratories by 696.0% in the 2nd quarter. Clearbridge Investments LLC now owns 352,814 shares of the company's stock valued at $171,891,000 after purchasing an additional 308,493 shares in the last quarter. Finally, Vontobel Holding Ltd. raised its position in shares of IDEXX Laboratories by 3,325.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company's stock valued at $111,229,000 after purchasing an additional 213,731 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several research reports. Piper Sandler reissued a "neutral" rating and set a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Barclays dropped their price target on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Finally, Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research note on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $552.38.

IDEXX Laboratories Price Performance

IDXX stock traded down $1.31 during trading hours on Friday, hitting $417.24. 503,442 shares of the stock traded hands, compared to its average volume of 775,938. The stock has a 50-day simple moving average of $460.86 and a 200 day simple moving average of $480.70. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company has a market cap of $34.17 billion, a P/E ratio of 40.24, a P/E/G ratio of 3.65 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analysts' expectations of $980.32 million. During the same quarter last year, the business posted $2.53 earnings per share. The company's quarterly revenue was up 6.6% on a year-over-year basis. Equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.